{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"26.3","value":"13.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"MEDIAN","populationDescription":"Participants with objective response among the intention to treat population","reportingStatus":"POSTED","timeFrame":"up to approximately 3 years","title":"Duration of Objective Response by Kaplan-Meier Analysis","type":"SECONDARY","unitOfMeasure":"months"}